Genmab, GSK Report Mid-Term Findings for Leukemia Drug

Based on promising interim results from a Phase III study in patients with refractory chronic lymphocytic leukemia, Genmab and GlaxoSmithKline (GSK) expect to file a BLA for HuMax-CD20 by the end of the year.

HuMax-CD20 (ofatumumab) is an investigational antibody that targets the small loop epitope of the CD20 molecule on B cells.

In the pivotal study, the drug induced a partial response in 30 of 59 patients resistant to treatment with fludarabine and Genzyme and Bayer Healthcare’s Campath (alemtuzumab), GenMab said.